Tags

Type your tag names separated by a space and hit enter

Treatment of depression with botulinum toxin A: a case series.
Dermatol Surg 2006; 32(5):645-9; discussion 649-50DS

Abstract

BACKGROUND

Major depression is a common and serious disease that may be resistant to routine pharmacologic and psychotherapeutic treatment approaches.

OBJECTIVE

To evaluate the efficacy of botulinum toxin A treatment of glabellar frown lines in treating patients with major depression, using a small open pilot trial.

METHODS

Patients who met DSM-IV criteria for ongoing major depression in spite of pharmacologic or psychotherapeutic treatment were evaluated with the Beck Depression Inventory II (BDI-II) before receiving botulinum toxin A to their glabellar frown lines. Two months later, all patients were re-evaluated clinically and with the BDI-II.

RESULTS

Ten depressed patients were treated with botulinum toxin A, and 9 of 10 patients were no longer depressed 2 months after treatment. The tenth patient had an improvement in mood.

CONCLUSION

To our knowledge, these are the first reported cases of depression treated with botulinum toxin A.

Authors+Show Affiliations

Dermatology and Cosmetic Surgery Associates, Greenbelt, Maryland, USA. efinzi@starpower.netNo affiliation info available

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

16706759

Citation

Finzi, Eric, and Erika Wasserman. "Treatment of Depression With Botulinum Toxin A: a Case Series." Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.], vol. 32, no. 5, 2006, pp. 645-9; discussion 649-50.
Finzi E, Wasserman E. Treatment of depression with botulinum toxin A: a case series. Dermatol Surg. 2006;32(5):645-9; discussion 649-50.
Finzi, E., & Wasserman, E. (2006). Treatment of depression with botulinum toxin A: a case series. Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.], 32(5), pp. 645-9; discussion 649-50.
Finzi E, Wasserman E. Treatment of Depression With Botulinum Toxin A: a Case Series. Dermatol Surg. 2006;32(5):645-9; discussion 649-50. PubMed PMID: 16706759.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of depression with botulinum toxin A: a case series. AU - Finzi,Eric, AU - Wasserman,Erika, PY - 2006/5/19/pubmed PY - 2006/6/29/medline PY - 2006/5/19/entrez SP - 645-9; discussion 649-50 JF - Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] JO - Dermatol Surg VL - 32 IS - 5 N2 - BACKGROUND: Major depression is a common and serious disease that may be resistant to routine pharmacologic and psychotherapeutic treatment approaches. OBJECTIVE: To evaluate the efficacy of botulinum toxin A treatment of glabellar frown lines in treating patients with major depression, using a small open pilot trial. METHODS: Patients who met DSM-IV criteria for ongoing major depression in spite of pharmacologic or psychotherapeutic treatment were evaluated with the Beck Depression Inventory II (BDI-II) before receiving botulinum toxin A to their glabellar frown lines. Two months later, all patients were re-evaluated clinically and with the BDI-II. RESULTS: Ten depressed patients were treated with botulinum toxin A, and 9 of 10 patients were no longer depressed 2 months after treatment. The tenth patient had an improvement in mood. CONCLUSION: To our knowledge, these are the first reported cases of depression treated with botulinum toxin A. SN - 1076-0512 UR - https://www.unboundmedicine.com/medline/citation/16706759/Treatment_of_depression_with_botulinum_toxin_A:_a_case_series_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=1076-0512&date=2006&volume=32&issue=5&spage=645 DB - PRIME DP - Unbound Medicine ER -